Trial Outcomes & Findings for Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity? (NCT NCT02939742)

NCT ID: NCT02939742

Last Updated: 2026-06-30

Results Overview

Mean number of days participants remained admitted to the Neonatal Intensive Care Unit (NICU) during hospitalization following birth.

Recruitment status

TERMINATED

Study phase

PHASE2/PHASE3

Target enrollment

33 participants

Primary outcome timeframe

daily from birth of infant up to one year or discharge from the NICU, whichever occurred first

Results posted on

2026-06-30

Participant Flow

Participant milestones

Participant milestones
Measure
Betamethasone
Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart. Betamethasone: Betamethasone 12mg IM given every 24 hours for two doses
Saline Placebo
Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart. Placebo: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
Overall Study
STARTED
17
16
Overall Study
COMPLETED
17
16
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity?

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Betamethasone
n=17 Participants
Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart. Betamethasone: Betamethasone 12mg IM given every 24 hours for two doses
Saline Placebo
n=16 Participants
Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart. Placebo: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
Total
n=33 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=20 Participants
0 Participants
n=20 Participants
0 Participants
n=40 Participants
Age, Categorical
Between 18 and 65 years
17 Participants
n=20 Participants
16 Participants
n=20 Participants
33 Participants
n=40 Participants
Age, Categorical
>=65 years
0 Participants
n=20 Participants
0 Participants
n=20 Participants
0 Participants
n=40 Participants
Sex: Female, Male
Female
17 Participants
n=20 Participants
16 Participants
n=20 Participants
33 Participants
n=40 Participants
Sex: Female, Male
Male
0 Participants
n=20 Participants
0 Participants
n=20 Participants
0 Participants
n=40 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=20 Participants
0 Participants
n=20 Participants
0 Participants
n=40 Participants
Race (NIH/OMB)
Asian
0 Participants
n=20 Participants
0 Participants
n=20 Participants
0 Participants
n=40 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=20 Participants
0 Participants
n=20 Participants
0 Participants
n=40 Participants
Race (NIH/OMB)
Black or African American
4 Participants
n=20 Participants
5 Participants
n=20 Participants
9 Participants
n=40 Participants
Race (NIH/OMB)
White
13 Participants
n=20 Participants
11 Participants
n=20 Participants
24 Participants
n=40 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=20 Participants
0 Participants
n=20 Participants
0 Participants
n=40 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=20 Participants
0 Participants
n=20 Participants
0 Participants
n=40 Participants
Region of Enrollment
United States
17 participants
n=20 Participants
16 participants
n=20 Participants
33 participants
n=40 Participants

PRIMARY outcome

Timeframe: daily from birth of infant up to one year or discharge from the NICU, whichever occurred first

Population: Neonates were assessed for this Outcome Measure.

Mean number of days participants remained admitted to the Neonatal Intensive Care Unit (NICU) during hospitalization following birth.

Outcome measures

Outcome measures
Measure
Saline Placebo
n=16 Participants
Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart. Placebo: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
Betamethasone
n=17 Participants
Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart. Betamethasone: Betamethasone 12mg IM given every 24 hours for two doses
Average Number of Days in the Neonatal Intensive Care Unit (NICU)
29.93 days
Interval 1.0 to 124.0
29.41 days
Interval 2.0 to 79.0

SECONDARY outcome

Timeframe: assessed daily up to 120 days after birth or discharge from hospital, whichever occured first

Population: Neonates were assessed for this Outcome Measure.

defined as ≥ 1 of the following: RDS (oxygen requirement, clinical diagnosis, and consistent chest radiograph), bronchopulmonary dysplasia (requirement for oxygen support at 30 days of life), severe IVH (grades III or IV), periventricular leukomalacia, blood culture-proven sepsis, necrotizing enterocolitis, or perinatal death (stillbirth or death before neonatal hospital discharge)

Outcome measures

Outcome measures
Measure
Saline Placebo
n=16 Participants
Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart. Placebo: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
Betamethasone
n=17 Participants
Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart. Betamethasone: Betamethasone 12mg IM given every 24 hours for two doses
Number of Participants With Composite Neonatal Morbidity
Respiratory Distress Syndrome (RDS)
8 Participants
6 Participants
Number of Participants With Composite Neonatal Morbidity
Bronchopulmonary Dysplasia
2 Participants
4 Participants
Number of Participants With Composite Neonatal Morbidity
Severe IVH
0 Participants
0 Participants
Number of Participants With Composite Neonatal Morbidity
Periventricular Leukomalacia
0 Participants
0 Participants
Number of Participants With Composite Neonatal Morbidity
Blood Culture-Proven Sepsis
0 Participants
0 Participants
Number of Participants With Composite Neonatal Morbidity
Necrotizing Enterocolitis
0 Participants
0 Participants
Number of Participants With Composite Neonatal Morbidity
Perinatal Death
1 Participants
1 Participants

SECONDARY outcome

Timeframe: daily from birth until discharge from the NICU or up to 1 year of age, whichever occurred first.

Population: Neonates were assessed for this Outcome Measure.

Amount of time, expressed in days from birth, that the infant required supplemental oxygen of any form, including nasal cannula, positive airway pressure, or ventilatory support. Reported as the mean number of days participants required supplemental oxygen therapy or ventilatory support.

Outcome measures

Outcome measures
Measure
Saline Placebo
n=16 Participants
Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart. Placebo: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
Betamethasone
n=17 Participants
Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart. Betamethasone: Betamethasone 12mg IM given every 24 hours for two doses
Average Number of Days Requiring Supplemental Oxygen or Ventilatory Support
29.93 days
Interval 1.0 to 124.0
29.41 days
Interval 2.0 to 79.0

SECONDARY outcome

Timeframe: assessed daily up to 120 days after birth or discharge from hospital, whichever occurred first

Population: Neonates were assessed for this Outcome Measure

Will be quantified as either present or absent. RDS defined as: compatible symptoms with radiographic evidence of hyaline membrane disease or respiratory insufficiency of prematurity requiring ventilatory support for ≥ 24 hrs

Outcome measures

Outcome measures
Measure
Saline Placebo
n=16 Participants
Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart. Placebo: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
Betamethasone
n=17 Participants
Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart. Betamethasone: Betamethasone 12mg IM given every 24 hours for two doses
Number of Participants Who Developed Respiratory Distress Syndrome (RDS)
8 Participants
6 Participants

SECONDARY outcome

Timeframe: assessed daily up to 120 days after birth or discharge from hospital, whichever occurred first

Population: Neonates were assessed for this Outcome Measure.

Will be quantified as either present or absent. Grade III IVH defined as ventricles enlarged by accumulating blood. Grade IV IVH defined as bleeding extending into brain matter around the ventricles.

Outcome measures

Outcome measures
Measure
Saline Placebo
n=16 Participants
Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart. Placebo: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
Betamethasone
n=17 Participants
Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart. Betamethasone: Betamethasone 12mg IM given every 24 hours for two doses
Grade III or IV Intraventricular Hemorrhage (IVH)
Grade III Intraventricular Hemorrhage (IVH)
0 Participants
0 Participants
Grade III or IV Intraventricular Hemorrhage (IVH)
Grade IV Intraventricular Hemorrhage (IVH)
0 Participants
0 Participants

SECONDARY outcome

Timeframe: daily up to 72 hours of life

Population: Neonates were assessed for this Outcome Measure.

confirmed by culture in the first 72 hours of life

Outcome measures

Outcome measures
Measure
Saline Placebo
n=16 Participants
Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart. Placebo: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
Betamethasone
n=17 Participants
Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart. Betamethasone: Betamethasone 12mg IM given every 24 hours for two doses
Number of Participants With Neonatal Sepsis
0 Participants
0 Participants

SECONDARY outcome

Timeframe: assessed daily up to 120 days after birth or discharge from hospital, whichever occurred first

Population: Neonates were assessed for this Outcome Measure.

Will be quantified as either present or absent. Stage 2 NEC will be defined as mild to moderate systemic illness, absent bowel sounds, abdominal tenderness, pneumatosis intestinalis or portal venous gas, metabolic acidosis, decreased platelets. Stage 3 NEC will be defined as severely ill, marked distention, signs of peritonitis, hypotension, metabolic \& respiratory acidosis, disseminated intravascular coagulopathy, pneumoperitoneum if bowel perforation present.

Outcome measures

Outcome measures
Measure
Saline Placebo
n=16 Participants
Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart. Placebo: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
Betamethasone
n=17 Participants
Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart. Betamethasone: Betamethasone 12mg IM given every 24 hours for two doses
Number of Participants With Necrotizing Enterocolitis (NEC) Stage 2 or 3
Necrotizing Enterocolitis (NEC) Stage 2
0 Participants
0 Participants
Number of Participants With Necrotizing Enterocolitis (NEC) Stage 2 or 3
Necrotizing Enterocolitis (NEC) Stage 3
0 Participants
0 Participants

SECONDARY outcome

Timeframe: assessed daily up to 120 days after birth or discharge from hospital, whichever occurred first

Population: Neonates were assessed for this Outcome Measure.

defined as stillbirth or death before neonatal discharge

Outcome measures

Outcome measures
Measure
Saline Placebo
n=16 Participants
Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart. Placebo: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
Betamethasone
n=17 Participants
Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart. Betamethasone: Betamethasone 12mg IM given every 24 hours for two doses
Number of Perinatal Death(s)
1 Participants
1 Participants

OTHER_PRE_SPECIFIED outcome

Timeframe: time from admission to delivery up to one year, or through study completion

time from diagnosis of PPROM from admission until delivery of neonate or until completion of the study

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: time from admission until maternal discharge from the hospital and up until 6 weeks postpartum, or through study completion

Chorioamnionitis will be defined as at least one temperature elevation above 38°C combined with at least two of the following signs: maternal or fetal tachycardia, uterine tenderness, foul smelling vaginal discharge, white blood count \> 18,000. Postpartum endometritis will be defined as postpartum temperature elevation above 38°C without other localizing sources of infection and with either uterine tenderness or foul-smelling lochia.

Outcome measures

Outcome data not reported

Adverse Events

Betamethasone

Serious events: 0 serious events
Other events: 0 other events
Deaths: 1 deaths

Saline Placebo

Serious events: 0 serious events
Other events: 0 other events
Deaths: 1 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Gayle Olson Koutrouvelis MD, MPH

UTMB

Phone: 409-747-4905

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place